*Refresh the page if the below document does not appear.
Indonesia puts a ban of cough syrup materials linked to Gambian Children deaths
The NA-DFC (National Agency of Drug and Food Control) of Indonesia called BPOM has set a standard that at the time of registration all the medicinal syrups either for adults or children are not allowed to use diethylene glycol (DEG) and ethylene glycol (EG) as they have been found to be responsible for causing acute kidney damage.
Madras High Court questions if Pharma companies involved in spread of diseases
On Friday, Madras high court asked the Tamil Nadu health department to investigate if any pharmaceutical industry is involved in the spread of viral diseases such as COVID-19 and Monkeypox to leverage it for their profit. The court has also instructed the department enquire and report the reason behind the continuous spread of the virus.
CDSCO Subject Expert Committee grants approval to study Anti Allergic combination drug
The CDSCO panel has given approval to Synokem Pharmaceuticals to conduct a Phase III clinical trial for the combination drug Montelukast-4mg (leukotriene receptor antagonist) plus Fexofenadine Hydrochloride60mg (antihistamine) Suspension indicated for the treatment of allergies.
Maiden Pharma appears to have 'forged' raw materials test reports
Maiden Pharma with its manufaturing facility in Sonepat, is the company whose cough syrups were under the scanner to be associated with the death of Gambian children. Documents examined by ‘The Tribune’ indicated that the company might have forged the test reports for the chemicals such as propylene glycol which were used in the cough syrups.
Shrinking vaccine market makes big Pharma companies change gears
On Sunday, Financial Times reported that the health data analytics group Airfinity has found covid vaccine deliveries to drop by nearly half in 2023. This might adversely affect the vaccine bigshots like Pfizer, BioNTech, and Moderna involved in the vaccine making bussiness.
CDSCO panel permits Sun Pharma to study Elagolix
CDSCO’s Subject Expert Committee (SEC) gave a nod to Pharma giant Sun Pharma to study the gonadotropin-releasing hormone receptor antagonist “Elagolix” (150 and 200 mg) used to treat moderate to severe pain in endometriosis.
CDMO Adragos Pharma buys Sanofi's 50 yearold plant in Japan
Adragos Pharma, the Germany-based CDMO
(Contract Development and Manufacturing
Organization) has signed a contract with Sanofi
K.K for the acquisition of a pharmaceutical
manufacturing facility in Kawagoe, Tokyo. It
produces over 70 products and the distribution
of Sanofi products in the Japanese market used
to take place from this site itself.